1597 related articles for article (PubMed ID: 26149185)
1. Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: associations with cytokine profiles, clinical and genetic features.
Reyes-Castillo Z; Palafox-Sánchez CA; Parra-Rojas I; Martínez-Bonilla GE; del Toro-Arreola S; Ramírez-Dueñas MG; Ocampo-Bermudes G; Muñoz-Valle JF
Clin Exp Immunol; 2015 Nov; 182(2):119-31. PubMed ID: 26149185
[TBL] [Abstract][Full Text] [Related]
2. Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients.
Snir O; Widhe M; Hermansson M; von Spee C; Lindberg J; Hensen S; Lundberg K; Engström A; Venables PJ; Toes RE; Holmdahl R; Klareskog L; Malmström V
Arthritis Rheum; 2010 Jan; 62(1):44-52. PubMed ID: 20039432
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: an Italian multicentric study and review of the literature.
Bartoloni E; Alunno A; Bistoni O; Bizzaro N; Migliorini P; Morozzi G; Doria A; Mathieu A; Lotzniker M; Allegri F; Riccieri V; Alpini C; Gabrielli A; Tampoia M; Gerli R;
Autoimmun Rev; 2012 Sep; 11(11):815-20. PubMed ID: 22394488
[TBL] [Abstract][Full Text] [Related]
4. Selected cyclic citrullinated peptides derived from the sequence of mutated and citrullinated vimentin (MCV) are targeted by different antibodies subclasses in patients with rheumatoid arthritis in Russian patients.
Derganova O; Martinez-Gamboa L; Egerer K; Bang H; Fredenhagen G; Roggenbuck D; Esaulenko I; Burmester GR; Chernykh T; Feist E
Clin Exp Rheumatol; 2014; 32(5):622-9. PubMed ID: 25189876
[TBL] [Abstract][Full Text] [Related]
5. Polymorphisms and functional haplotype in PADI4: further evidence for contribution on rheumatoid arthritis susceptibility and anti-cyclic citrullinated peptide antibodies in a western Mexican population.
Guzmán-Guzmán IP; Reyes-Castillo Z; Muñoz-Barrios S; Ruiz-Noa Y; Martínez-Bonilla GE; Parra-Rojas I; Palafox-Sánchez CA; Muñoz-Valle JF
Immunol Lett; 2015 Feb; 163(2):214-20. PubMed ID: 25562673
[TBL] [Abstract][Full Text] [Related]
6. Comparison of anti-mutated citrullinated vimentin, anti-cyclic citrullinated peptides, anti-glucose-6-phosphate isomerase and anti-keratin antibodies and rheumatoid factor in the diagnosis of rheumatoid arthritis in Chinese patients.
Zhu T; Feng L
Int J Rheum Dis; 2013 Apr; 16(2):157-61. PubMed ID: 23773638
[TBL] [Abstract][Full Text] [Related]
7. Genetic background of anticyclic citrullinated peptide autoantibody production in Hungarian patients with rheumatoid arthritis.
Poór G; Nagy ZB; Schmidt Z; Brózik M; Merétey K; Gergely P
Ann N Y Acad Sci; 2007 Sep; 1110():23-32. PubMed ID: 17911417
[TBL] [Abstract][Full Text] [Related]
8. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides.
Mathsson L; Mullazehi M; Wick MC; Sjöberg O; van Vollenhoven R; Klareskog L; Rönnelid J
Arthritis Rheum; 2008 Jan; 58(1):36-45. PubMed ID: 18163519
[TBL] [Abstract][Full Text] [Related]
9. Association of anti-modified citrullinated vimentin with subclinical atherosclerosis in early rheumatoid arthritis compared with anti-cyclic citrullinated peptide.
El-Barbary AM; Kassem EM; El-Sergany MA; Essa SA; Eltomey MA
J Rheumatol; 2011 May; 38(5):828-34. PubMed ID: 21362765
[TBL] [Abstract][Full Text] [Related]
10. An investigation of the added value of an ACPA multiplex assay in an early rheumatoid arthritis setting.
van Heemst J; Trouw LA; Nogueira L; van Steenbergen HW; van der Helm-van Mil AH; Allaart CF; Serre G; Holmdahl R; Huizinga TW; Toes RE; van der Woude D
Arthritis Res Ther; 2015 Oct; 17():276. PubMed ID: 26437716
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic value of anti-modified citrullinated vimentin in rheumatoid arthritis.
Maraina CH; Nurdayana AK; Rusni D; Azwany Y
Int J Rheum Dis; 2010 Oct; 13(4):335-9. PubMed ID: 21199468
[TBL] [Abstract][Full Text] [Related]
12. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides.
Innala L; Kokkonen H; Eriksson C; Jidell E; Berglin E; Dahlqvst SR
J Rheumatol; 2008 Jun; 35(6):1002-8. PubMed ID: 18398946
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic utility of anti-cyclic citrullinated peptide and anti-modified citrullinated vimentin antibodies in rheumatoid arthritis.
Keskin G; Inal A; Keskin D; Pekel A; Baysal O; Dizer U; Sengül A
Protein Pept Lett; 2008; 15(3):314-7. PubMed ID: 18336364
[TBL] [Abstract][Full Text] [Related]
14. Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis.
Soós L; Szekanecz Z; Szabó Z; Fekete A; Zeher M; Horváth IF; Dankó K; Kapitány A; Végvári A; Sipka S; Szegedi G; Lakos G
J Rheumatol; 2007 Aug; 34(8):1658-63. PubMed ID: 17611988
[TBL] [Abstract][Full Text] [Related]
15. [Significance and diagnostic value of synovial fluid anti-cyclic citrullinated peptide antibody and anti-mutated citrullinated vimentin antibodies in patients with serum negative rheumatoid arthritis].
Qu SJ; Ye H; Jia RL; Li ZG
Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Dec; 48(6):933-936. PubMed ID: 27987492
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of soluble peptidylarginine deiminase 4 (PAD4) and anti-PAD4 antibodies in autoimmune diseases.
Umeda N; Matsumoto I; Kawaguchi H; Kurashima Y; Kondo Y; Tsuboi H; Ogishima H; Suzuki T; Kagami Y; Sakyu T; Ishigami A; Maruyama N; Sumida T
Clin Rheumatol; 2016 May; 35(5):1181-8. PubMed ID: 26415740
[TBL] [Abstract][Full Text] [Related]
17. [Association between the synovial expression of cyclic citrullinated peptide and susceptibility variants of HLA-DRB1 shared epitope alleles and PADI 4 gene single nucleotide polymorphisms in patients with rheumatoid arthritis].
Li HB; Tie N; Jia YF; Shi L; Su Y; Zhang GZ; Wang Y; Bai LJ; Zhao J; Wang J; Xiao Z
Zhonghua Yi Xue Za Zhi; 2012 Jun; 92(23):1607-11. PubMed ID: 22944128
[TBL] [Abstract][Full Text] [Related]
18. The anti-mutated citrullinated vimentin response classifies patients with rheumatoid arthritis into broad and narrow responders.
Engelmann R; Brandt J; Eggert M; Karberg K; Krause A; Neeck G; Mueller-Hilke B
J Rheumatol; 2009 Dec; 36(12):2670-4. PubMed ID: 19884278
[TBL] [Abstract][Full Text] [Related]
19. Antibodies binding to citrullinated telopeptides of type I and type II collagens and to mutated citrullinated vimentin synergistically predict the development of seropositive rheumatoid arthritis.
Koivula MK; Heliövaara M; Rissanen H; Palosuo T; Knekt P; Immonen H; Risteli J
Ann Rheum Dis; 2012 Oct; 71(10):1666-70. PubMed ID: 22419777
[TBL] [Abstract][Full Text] [Related]
20. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]